These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 469238)

  • 1. Aluminium sucrose biscuits in the treatment of hyperphosphataemia.
    Morgan J; Gabriel R
    J Hum Nutr; 1979 Jun; 33(3):231-2. PubMed ID: 469238
    [No Abstract]   [Full Text] [Related]  

  • 2. [Aluminum hydroxide treatment of hyperphosphatemia in uremia].
    Bergquist-Poppen M; Bergström J; Wallin R
    Lakartidningen; 1972 May; 69(19):2319-20. PubMed ID: 5035811
    [No Abstract]   [Full Text] [Related]  

  • 3. Calcium carbonate as an alternative to aluminium hydroxide in maintenance haemodialysis for chronic renal failure.
    O'Brien A; McParland C; Keogh B
    Ir Med J; 1987 Feb; 80(2):68-70. PubMed ID: 3557928
    [No Abstract]   [Full Text] [Related]  

  • 4. [Iatrogenic aluminum osteopathy in a uremic infant].
    Koch H; Reich H; Franke D; Delling G
    Monatsschr Kinderheilkd; 1986 May; 134(5):279-81. PubMed ID: 3724766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Methods of correcting hyperphosphatemia in chronic renal failure and in dialysis (review)].
    Novikov AI
    Ter Arkh; 1997; 69(12):63-7. PubMed ID: 9503540
    [No Abstract]   [Full Text] [Related]  

  • 6. Phosphate binders in hyperphosphatemia of chronic renal failure.
    Wasan SM; Godley PJ
    DICP; 1991 Sep; 25(9):942-5. PubMed ID: 1949972
    [No Abstract]   [Full Text] [Related]  

  • 7. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcium carbonate in hyperphosphatemia.
    Mayo M; Middleton RK
    DICP; 1991 Sep; 25(9):945-7. PubMed ID: 1949973
    [No Abstract]   [Full Text] [Related]  

  • 9. The effects of zero magnesium dialysate and magnesium supplements on ionised calcium concentration in patients on regular dialysis treatment.
    Breuer J; Moniz C; Baldwin D; Parsons V
    Nephrol Dial Transplant; 1987; 2(5):347-50. PubMed ID: 3122112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the control of phosphate in the progression of chronic renal failure.
    Barrientos A; Arteaga J; Rodicio JL; Alvarez Ude F; Alcazar JM; Ruilope LM
    Miner Electrolyte Metab; 1982 Mar; 7(3):127-33. PubMed ID: 7169978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aluminium encephalopathy: a potential risk of aluminium gels in children with chronic renal failure.
    Pillion G; Loirat C; Blum C; Poisson M; Bacri JL; Broyer M; Mathieu H
    Int J Pediatr Nephrol; 1981 Mar; 2(1):29-32. PubMed ID: 7333766
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of lowering the serum phosphate on parathyroid hormone secretion and total serum calcium during regular hemodialysis.
    Hill AV; Thein-Than ; Cook DB; Derr KN; Latner AL
    Clin Nephrol; 1973; 1(5):284-9. PubMed ID: 4797465
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of a new phosphate binder in chronic renal insufficiency.
    Rutherford E; King S; Perry B; Blondin J; Finley T; Mason N; Sparks R; Slatopolsky E
    Kidney Int; 1980 Apr; 17(4):528-34. PubMed ID: 7392426
    [No Abstract]   [Full Text] [Related]  

  • 14. [Administration of colloidal aluminium hydroxide to patients under chronic hemodialysis].
    Vokrouhlická O; Erben J; Zahradník J; Dvoráková-Bastecká D
    Cas Lek Cesk; 1977 May; 116(19):594-7. PubMed ID: 880597
    [No Abstract]   [Full Text] [Related]  

  • 15. Aluminium sucrose biscuit fillings to control hyperphosphataemia in patients undergoing dialysis.
    Gabriel R; Morgan J
    Br Med J (Clin Res Ed); 1981 Jul; 283(6286):268. PubMed ID: 6788282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Calcium carbonate for the treatment of hyperphosphatemia in chronic hemodialysis patients].
    Kiss D; Battegay M; Meier C; Lyrer A
    Schweiz Med Wochenschr; 1990 Mar; 120(9):295-8. PubMed ID: 2315655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [How far should the serum concentration of inorganic phosphate be lowered in patients with chronic uremia?].
    Eigler J; Grabensee B; Henning HV
    Med Welt; 1982 Jan; 33(4):115-6. PubMed ID: 7062836
    [No Abstract]   [Full Text] [Related]  

  • 18. Aluminum-free intestinal phosphate binding.
    Schneider H; Kulbe KD; Weber H; Streicher E
    Contrib Nephrol; 1984; 38():32-6. PubMed ID: 6713898
    [No Abstract]   [Full Text] [Related]  

  • 19. Oral aluminium hydroxide in the treatment of hyperphosphatemia and acidosis in acute and chronic renal insufficiency.
    LINDHOLM T
    Acta Med Scand; 1962 Jul; 172():75-8. PubMed ID: 14465480
    [No Abstract]   [Full Text] [Related]  

  • 20. Aluminum, zinc and copper concentrations in plasma in chronic renal insufficiency.
    Zumkley H; Bertram HP; Lison A; Knoll O; Losse H
    Clin Nephrol; 1979 Jul; 12(1):18-21. PubMed ID: 477052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.